Authors:
Liu, M
Bishop, WR
Nielsen, LL
Bryant, MS
Kirschmeier, P
Citation: M. Liu et al., Orally bioavailable farnesyltransferase inhibitors as anticancer agents intransgenic and xenograft models, METH ENZYM, 333, 2001, pp. 306-318
Authors:
Wang, LQ
Wu, Q
Qiu, P
Mirza, A
McGuirk, M
Kirschmeier, P
Greene, JR
Wang, YL
Pickett, CB
Liu, SX
Citation: Lq. Wang et al., Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches, J BIOL CHEM, 276(47), 2001, pp. 43604-43610
Authors:
Ashar, HR
James, L
Gray, K
Carr, D
McGuirk, M
Maxwell, E
Black, S
Armstrong, L
Doll, RJ
Taveras, AG
Bishop, WR
Kirschmeier, P
Citation: Hr. Ashar et al., The farnesyl transferase inhibitor SCH 66336 induces a G(2) -> M or G(1) pause in sensitive human tumor cell lines, EXP CELL RE, 262(1), 2001, pp. 17-27
Authors:
Peters, DG
Hoover, RR
Gerlach, MJ
Koh, EY
Zhang, HY
Choe, K
Kirschmeier, P
Bishop, WR
Daley, GQ
Citation: Dg. Peters et al., Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia, BLOOD, 97(5), 2001, pp. 1404-1412
Authors:
Bishop, WR
Pai, JJK
Armstrong, L
Dalton, MB
Doll, RJ
Taveras, A
Njoroge, G
Sinensky, M
Zhang, F
Liu, M
Kirschmeier, P
Citation: Wr. Bishop et al., Tricyclic farnesyl protein transferase inhibitors - Antitumor activity andeffects on protein prenylation, CANC DRUG, 8, 2001, pp. 87-101
Authors:
Ashar, HR
James, L
Gray, K
Carr, D
Black, S
Armstrong, L
Bishop, WR
Kirschmeier, P
Citation: Hr. Ashar et al., Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules, J BIOL CHEM, 275(39), 2000, pp. 30451-30457
Authors:
Adjei, AA
Erlichman, C
Davis, JN
Cutler, DL
Sloan, JA
Marks, RS
Hanson, LJ
Svingen, PA
Atherton, P
Bishop, WR
Kirschmeier, P
Kaufmann, SH
Citation: Aa. Adjei et al., A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity, CANCER RES, 60(7), 2000, pp. 1871-1877
Authors:
Njoroge, FG
Vibulbhan, B
Bishop, WR
Kirschmeier, P
Bryant, MS
Nomeir, AA
Liu, M
Doll, RJ
Girijavallabhan, VM
Ganguly, AK
Citation: Fg. Njoroge et al., Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity, BIO MED CH, 7(5), 1999, pp. 861-867
Authors:
Liu, M
Bryant, MS
Chen, JP
Lee, SN
Yaremko, B
Li, ZJ
Dell, J
Lipari, P
Malkowski, M
Prioli, N
Rossman, RR
Korfmacher, WA
Nomeir, AA
Lin, CC
Mallams, AK
Doll, RJ
Catino, JJ
Girijavallabhan, VM
Kirschmeier, P
Bishop, WR
Citation: M. Liu et al., Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice, CANC CHEMOT, 43(1), 1999, pp. 50-58
Authors:
Taveras, AG
Deskus, J
Chao, JP
Vaccaro, CJ
Njoroge, FG
Vibulbhan, B
Pinto, P
Remiszewski, S
del Rosario, J
Doll, RJ
Alvarez, C
Lalwani, T
Mallams, AK
Rossman, RR
Afonso, A
Girijavallabhan, VM
Ganguly, AK
Pramanik, B
Heimark, L
Bishop, WR
Wang, L
Kirschmeier, P
James, L
Carr, D
Patton, R
Bryant, MS
Nomeir, AA
Liu, M
Citation: Ag. Taveras et al., Identification of pharmacokinetically stable 3,10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities, J MED CHEM, 42(14), 1999, pp. 2651-2661